Sugi Predict

Sugi Predict / Targets / LY96

LY96

Lymphocyte antigen 96 · Q9Y6Y9 · LY96 on Sugi Atlas →

6,474 patent compounds predicted against LY96, 4,132 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1724181 SCHEMBL1724181 0.61 7/20
SCHEMBL2338181 SCHEMBL2338181 0.57 6/20
SCHEMBL1722335 SCHEMBL1722335 0.55 6/20
SCHEMBL1933335 SCHEMBL1933335 0.52 6/20
SCHEMBL1933809 SCHEMBL1933809 0.52 6/20
SCHEMBL2530849 SCHEMBL2530849 0.48 6/20
SCHEMBL118078 SCHEMBL118078 0.47 6/20
SCHEMBL2338089 SCHEMBL2338089 0.47 6/20
SCHEMBL2338095 SCHEMBL2338095 0.47 6/20
SCHEMBL2339239 SCHEMBL2339239 0.47 6/20
SCHEMBL2343353 SCHEMBL2343353 0.47 6/20
SCHEMBL806360 SCHEMBL806360 0.47 6/20
SCHEMBL2336007 SCHEMBL2336007 0.45 6/20
Eritoran Eritoran (SCHEMBL1650733) 0.41 6/20
SCHEMBL3731963 SCHEMBL3731963 0.41 6/20
SCHEMBL3733856 SCHEMBL3733856 0.41 6/20
SCHEMBL3739987 SCHEMBL3739987 0.41 6/20
SCHEMBL3957808 SCHEMBL3957808 0.35 6/20
SCHEMBL2755045 SCHEMBL2755045 0.56 5/20
SCHEMBL2755050 SCHEMBL2755050 0.53 5/20

Clinical trials — most relevant to LY96 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Belatacept 3 Month Post Transplant Conversion Study PHASE4COMPLETED
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis PHASE4COMPLETED
Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease PHASE2/PHASE3UNKNOWN
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders PHASE2COMPLETED
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma PHASE2COMPLETED
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma PHASE2COMPLETED
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma PHASE2COMPLETED
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma PHASE1/PHASE2COMPLETED
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma PHASE2COMPLETED
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma PHASE1/PHASE2COMPLETED
LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery PHASE2COMPLETED
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma PHASE1/PHASE2COMPLETED
Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) PHASE1COMPLETED
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC EARLY_PHASE1UNKNOWN
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence nanUNKNOWN
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis nanCOMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty nanUNKNOWN
Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD) nanNOT_YET_RECRUITING
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level nanCOMPLETED
Evaluation of Eosinophil Phenotype in COPD Patients nanUNKNOWN
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation nanCOMPLETED
The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LY96 binder may also engage these)

ProteinNameSimilarity
P58755 — 1.000 P58755 →
P58754 — 1.000 P58754 →
Q9JHF9 — 0.996 Q9JHF9 →
Q90890 — 0.994 Q90890 →
Q9AST8 — 0.993 Q9AST8 →
O95711 — 0.987 O95711 →
O88188 — 0.987 O88188 →
B0FHH8 — 0.985 B0FHH8 →
B3N7D5 — 0.984 B3N7D5 →
A0A888 — 0.984 A0A888 →
B4HYQ2 — 0.983 B4HYQ2 →
B4Q785 — 0.983 B4Q785 →
H2A0L2 — 0.983 H2A0L2 →
Q9VLJ0 — 0.982 Q9VLJ0 →
B4NXG9 — 0.982 B4NXG9 →
Q54MV4 — 0.982 Q54MV4 →
Q95UP9 — 0.982 Q95UP9 →
P60987 — 0.982 P60987 →
Q22125 — 0.982 Q22125 →
Q65C83 — 0.982 Q65C83 →
P25607 — 0.982 P25607 →
O18016 — 0.982 O18016 →
Q6GM71 — 0.981 Q6GM71 →
A0A8U0LTT9 — 0.981 A0A8U0LTT9 →
O94385 — 0.981 O94385 →
B4GJ61 — 0.981 B4GJ61 →
Q9FF98 — 0.981 Q9FF98 →
Q93105 — 0.981 Q93105 →
O45879 — 0.981 O45879 →
P53752 — 0.981 P53752 →